Most current therapies being investigated for neurodegenerative diseases target only a single type of misfolded protein, not addressing the fact that these diseases are often characterized by the buildup of multiple types of pathologic protein aggregates. Our scientists have developed a novel proprietary technology known as GAIM, or General Amyloid Interaction Motif, that simultaneously targets multiple misfolded proteins implicated in neurodegenerative diseases, potentially creating a more robust response that could be suitable for patients at all stages of disease progression.

Our GAIM-based therapies use a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including amyloid-β (Aβ) and tau, characteristics of Alzheimer’s disease. Our therapies are designed to prevent the further accumulation of aggregates and clear existing aggregates from the brain, while also blocking further cell-to-cell spread of misfolded proteins. We believe these therapies offer a breakthrough approach to treating protein misfolding diseases.

Proclara is developing several product candidates capable of targeting multiple misfolded proteins for the treatment of a broad range of aging diseases and certain orphan indications, including its lead development candidate, NPT088, which is currently in clinical development for Alzheimer’s disease.